We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Backs Spironolactone for New Heart Failure Indication
FDA Advisory Panel Backs Spironolactone for New Heart Failure Indication
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 8-4 on Wednesday, with one abstention, that findings from a study sponsored by the National Institutes of Health (NIH) could support new heart failure indications for the generic drug spironolactone.